Bright Minds Biosciences Inc. income statement DRUG
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|
| Weighted average shares, basic |
4
+15.9%
|
4
+50.6%
|
2
+37.6%
|
2
|
| Weighted average shares, diluted |
4
+15.9%
|
4
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRUG (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1827401
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.